Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

Inclusion Criteria: * Male and/or female patients between 40 and 85 years of age (both inclusive) * Diagnosis of mild Alzheimer's Disease (AD) * Mini-Mental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks. Exclusion Criteria: * Previously participated in an AD vaccine study and received active treatment. * History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition. * History or presence of seizures and/or cerebrovascular disease. * Presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression) * Advanced, severe, progressive or unstable disease that might interfere with the safety of the patient. Other protocol-defined inclusion/exclusion criteria may apply